HomeNewsMj biopharm

Mj Biopharm

Jump to

Eris Life's growth hunger can slow earnings

The Rs 650 crore Oaknet Healthcare acquisition gives Eris a foothold in the dermatology therapy drugs segment
Insulin complements Eris Lifesciences' diabetes portfolio, market share gains key

Eris' joint venture to market insulin adds a potential revenue stream, but product efficacy will play an important role in the success of the new venture
Eris Lifesciences jumps over 9% on MJ Biopharm tie-up for insulin market foray

Eris Lifesciences will hold 70 percent stake in the JV and engage in marketing and distribution of human and analogue insulins and GLP-1 agonists among other biopharma products in India

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Mj Biopharm

Eris Life's growth hunger can slow earnings

Insulin complements Eris Lifesciences' diabetes portfolio, market share gains key

Eris Lifesciences jumps over 9% on MJ Biopharm tie-up for insulin market foray